Chronic hepatitis B virus (HBV) infection and the integration of its X gene (HBx) are closely associated with the development of hepatocellular carcinoma (HCC). The integrated HBx frequently is truncated or contains point mutations. Previous studies indicated that these HBx mutants have a diminished co-transactivational activity. We have compared the eects of wildtype (wt) HBx and its naturally occurring mutants derived from human HCCs on transcriptional cotransactivation, apoptosis and interactive eects with p53. We demonstrated that overexpression of mutant, but not wt HBx, is defective in transcriptional cotransactivation of the NF-kB-driven luciferase reporter. By using a microinjection technique, the HBx mutants were shown to have an attenuated pro-apoptotic activity. This de®ciency may be attributed to multiple mutations in the co-transactivation domain of HBx, that leads to decreased stability of the translated product. However, wt or mutant HBx bind to p53 in vitro and retain their ability to block p53-mediated apoptosis in vivo, which has been implicated as its major tumor suppressor function. The abrogation of p53-mediated apoptosis by integrated HBx mutants may provide a selective clonal advantage for preneoplastic or neoplastic hepatocytes and contribute to hepatocellular carcinogenesis. Oncogene (2001) 20, 3620 ± 3628.
Introduction
The p53 tumor suppressor gene product is involved in the maintenance of genomic stability of cells (Lane, 1992; Levine, 1997; Schwartz and Rotter, 1998; Oren, 1999) . p53 has multiple functions, including transcriptional transactivation and repression, the regulation of factors involved in DNA repair, induction of cell apoptosis, and cell cycle control (Dulic et al., 1994; Wu and Levine, 1994; Schwartz and Rotter, 1998; Oren, 1999) . In addition, many DNA tumor viruses encode transforming oncoproteins that interact with p53, such as the large T antigen from SV40 (Lane and Crawford, 1979; Linzer and Levine, 1979) , E6 from human papillomavirus (Dyson et al., 1989) , E1B from adenovirus (Sarnow et al., 1982) , EBNA-5 from Epstein-Barr virus (Szekely et al., 1993) , IE84 from human cytomegalovirus (Speir et al., 1994) and the hepatitis B X (HBx) protein from hepatitis B virus (HBV) (Feitelson et al., 1993; Wang et al., 1994 Wang et al., , 1995 Ueda et al., 1995; Kew, 1996 Kew, , 1997 Doitsh and Shaul, 1999; Lee and Rho, 2000; Yun et al., 2000) . Disruption of transcriptional transactivation or p53-mediated apoptosis by viral oncoproteins is implicated in carcinogenesis.
Chronic HBV infection is a major risk factor associated with the development of hepatocellular carcinoma (HCC) (Beasley et al., 1981) . The product of the HBV X gene, HBx, can co-transactivate various cellular genes that engage in cell proliferation and an acute in¯ammation response (Hu et al., 1990; Unger and Shaul, 1990; Mahe et al., 1991; Avantaggiati et al., 1993; Twu et al., 1993; Caselmann, 1995) . As an oncoprotein, HBx can neoplastically transform rodent cells in vitro (Shirakata et al., 1989; Hohne et al., 1990; Seifer et al., 1991) and, as a transgene, it is capable of inducing HCC formation in mice (Kim et al., 1991; Yu et al., 1999) . HBx also may promote liver cell susceptibility to carcinogen-induced mutagenesis, including codon 249 ser p53 mutations (Sohn et al., 2000) , and bind to DNA repair proteins involved in nucleotide excision repair (Wang et al., 1994; Becker et al., 1998) . Moreover, the HBx gene frequently is integrated into the genome and expressed in HCC tissue from patients in the geographic areas of high liver cancer incidence (Unsal et al., 1994; Paterlini et al., 1995; Su et al., 1998; Chen et al., 2000) .
We and others have reported that p53 inactivation during human hepatocellular carcinogenesis may occur through p53 mutations (Bressac et al., 1991; Hsu et al., 1991; Aguilar et al., 1994) or direct interaction with HBx (Feitelson et al., 1993; Wang et al., 1995; Elmore et al., 1997; Doitsh and Shaul, 1999; Yun et al., 2000) . Several reports also provided evidence that HBx has the ability to induce cell apoptosis and sensitize cells to tumor necrosis factor (TNF)-a induced apoptosis (Chirillo et al., 1997; Su and Schneider, 1997; Kim et al., 1998; Takada et al., 1999) . Although the co-transactivation activity of HBx is considered its major oncogenic property (Andrisani and Barnabas, 1999) , the contribution of the other pleiotropic eects of HBx on cell cycle regulation and viability remains uncertain (Murakami, 1999; Brechot et al., 2000; Arbuthnot et al., 2000) . Recently, it was reported that naturally occurring HBx mutants, which were subcloned from human HCC tissues and contained multiple point mutations, lacked the anti-proliferative and co-transactivation ability of wt HBx . These ®ndings indicate that mutation in HBx may contribute to the development of HCC in HBV-infected patients. By using arti®cially engineered deletion mutants, we and others have investigated the binding between HBx and p53 by mapping the co-transactivation domains (Elmore et al., 1997; Lin et al., 1997) . However, the interaction between the naturally occurring HBx mutants and p53, and the eects of these mutants on p53-mediated apoptosis are unknown. Because the potential mechanism of these naturally occurring HBx mutants linked to neoplastic transformation remains uncertain, we compared the transcriptional co-transactivation activity of wt or mutant HBx constructs from tumor and non-tumor tissues of human HCC, their eects on apoptosis and their interaction with p53. Our results are consistent with the hypothesis that HBx mutants retain the ability to abrogate p53-induced apoptosis independent of their co-transactivation and pro-apoptotic activities as a contributory mechanism to human hepatocarcinogenesis.
Results

Both wild-type and mutant HBx abrogate p53-induced apoptosis
The plasmid constructs cloned from HCC patients with chronic HBV infection, which encoded wt (CNT: nontumor tissue in patient C) and mutant HBx genes (CT: tumor tissue in patient C; MNT: nontumor tissue in patient M; MT: tumor tissue in patient M), were described previously . The amino acid sequences of those HBx constructs are shown comparatively in Figure 1 . The sequence of the plasmid CNT matches the sequence of the subtype ayw of HBV exactly.
A microinjection strategy in primary human ®bro-blasts was employed to investigate the ability of wt and mutant HBx to inhibit p53-mediated apoptosis. In agreement with our previous report (Wang et al., 1995) , overexpression of p53 induces a high rate of cell death, and co-expression of wt HBx (CNT) blocks p53-mediated apoptosis (Figure 2a ). The apoptotic rate was decreased from an average of 24 to 7% (P50.01 by Student t-test) at 24 h, and the inhibitory eect was sustained up to 72 h after microinjection (69% vs 11%, Figure 2a ). Similarly, all HBx mutants (CT, MNT and MT) have the ability to abrogate p53-mediated apoptosis eciently at 24 h (7, 8 and 8%, respectively) and 72 h (7, 20 and 18%, respectively; all P values 50.01 by Student t-test; Figure 2a ). Apoptotic cells displayed typical characteristic features including cytoplasmic blebbing, nuclear condensation and/or fragmentation, and the appearance of apoptotic bodies (Figure 2b) . Notably, HBx expression vectors induced variable apoptotic rates when injected without p53, whereas wt HBx (CNT) induced a higher rate of apoptosis than HBx mutants (CT, MNT and MT) at 72 h (12% vs 5, 5 and 4%, respectively, P50.05, Student t-test; Figure 2a ).
The translated products of wt and mutant HBx bind to glutathione S-transferase-p53 fusion protein in vitro
To determine if the anti-apoptotic eects of HBx might be achieved through the physical interaction with p53, we performed in vitro protein ± protein binding assays by using 35 S-labeled in vitro translated HBx and glutathione S-transferase-p53 (GST-p53) fusion protein. In agreement with our previous results (Wang et al., 1995) , in vitro translated wt HBx speci®cally binds to GST-p53 fusion protein (Figure 3 
HBx mutants do not transactivate NF-kB-driven luciferase reporter activity
The ability to transcriptionally co-transactivate NFkB-driven luciferase reporter construct was compared between wt and mutant HBx. The HBx mutants (CT, MNT and MT) lacked the ability of co-transactivation whether they were treated with or without TNFa (10 ng/ml), an agent known to sensitize the eect of HBx to co-transactivate NF-kB, either at a ®xed dose (0.5 mg DNA; all P values 50.05 by Student t-test for the comparisons between wt and mutant HBx with or without TNFa; Figure 4a ) or over a wide range of DNA concentrations (0 ± 5 mg DNA; Figure 4b ) in Hep3B cells grown on 6-well plates. Western blot analysis of the cells transfected with corresponding HBx constructs showed that HBx mutants displayed a reduced steady state level when compared with wt HBx (Figure 5a) . Notably, the lack of the co-transactivation ability might be because of an impaired function of the translated products of mutant HBx, as the amount of translated proteins may be increased by proportionally increasing the dosages of DNA used for transfection (10, 20, 40 and 80 mg in 100-mm plates; Figure 5b ). However, there was no increase in the co-transactivation activity from the NF-kB luciferase reporter assay for the same HBx mutant (CT) over the corresponding transfection concentrations as shown in Figure 4b . We also determined whether HBx mutants were less stable in vivo. HBx-expressing cells were treated with a proteasome inhibitor, ALLN. There was a similar degree of elevated protein levels in both wt and mutants following treatment of ALLN ( Figure 5c ). These data suggest that both wt and mutant HBx proteins have a similar stability in vivo.
Discussion
The translated product of the HBx gene has been known as a promiscuous transcriptional co-transactivator. This has led to the hypothesis that the mechanism of HBx-mediated cellular transformation involves the deregulation of cellular gene expression by targeting cellular transactivators directly (Andrisani et al., 1999) . Whereas overexpression of HBx can increase neoplastic transformation in rodent cells (Terradillos et al., 1998) , several groups reported that overexpression of HBx can induce or enhance apoptosis in a p53-dependent or p53-independent manner (Chirillo et al., 1997; Su and Schneider 1997; Kim et al., 1998; Takada et al., 1999) . The ®nding that HBx can inhibit H-ras-or Bcl-2-mediated neoplastic transformation (Kim et al., 1998; Schuster et al., 2000) is consistent with its role in apoptosis. The molecular mechanisms of these divergent ®ndings of HBx are still highly debatable (Murakami, 1999; Brechot et al., 2000; Su et al., 2000) . Several lines of evidence have suggested that the intracellular concentrations of HBx might be a critical factor of the phenotypic eect of HBx (Feitelson and Duan, 1997; Schuster et al., 2000) . It has been reported that the level of HBx in cultured cell lines following ectopic expression is compatible with the level achieved during viral DNA replication (range: 0.8 ± 8610 4 molecules per cell) (Dandri et al., 1996; Su and Schneider, 1997) . These ®ndings argue the physiological relevance of the level of HBx using an in vitro ectopic expression system.
Previously, we have demonstrated that p53-mediated apoptosis is abrogated eciently by wt HBx (Wang et al., 1995; Elmore et al., 1997) . The inhibition of apoptosis may be a consequence of the failure of p53 to upregulate Bax, DR5 or to downregulate Bcl-2, which are involved in the activation of apoptosis (Wang, 1999) . Alternatively, HBx could aect p53 binding to the TFIIH DNA helicases, XPB and XPD, which are members of the p53-dependent apoptotic pathway (Wang et al., , 1995 Jia et al., 1999) . In this study, we showed that all of the HBx mutants tested retained their ability to block p53-mediated apoptosis. One possibility is that these mutants may physically bind to p53 and prevent p53-mediated activities. Our data that recombinant GST-p53 binds to HBx mutants in vitro are consistent with this hypothesis. However, the amount of the p53-HBx complex detected is small. Alternatively, the mutants may interfere with p53-mediated pathway by transcriptionally repressing the activation of p53 (Lee and Rho, 2000; Ogden et al., 2000) or displacing or inhibiting the binding of p53 to its downstream responsive elements (Truant et al., 1995) . Consistent with this hypothesis is the ®nding that the binding between p53 and HBx and the functional inhibition of p53 are reversible under certain genotoxic stimuli (Yun et al., 2000) . The ability of p53 to induce apoptosis has been recognized as an important mode of tumor suppressor function (Lane, 1992; Prives, 1993; Levine, 1997; Wang and Harris, 1997; Schwartz and Rotter, 1998; Oren, 1999) , and the inactivation of p53 by HBx may be a critical step in liver carcinogenesis.
In this study, we demonstrate that p53-induced apoptosis can be inhibited signi®cantly by either wt or mutant HBx. Although the HBx mutants lacked the ability to transcriptionally co-transactivate the NF-kBdriven luciferase reporter in Hep3B cells, the wt HBx protein still retained the ability of potential cotransactivation. These results indicate that the transcriptional co-transactivation ability of HBx was not correlated with its ability to abrogate p53-mediated apoptosis. Furthermore, we showed that wt HBx (CNT) can induce a higher rate of cell death than any of the HBx mutants (CT, MNT and MT) at 72 h (Figure 2a ). Consistent with a previous study , our results con®rmed that the pro-apoptotic and co-transactivation ability of HBx was preserved in wt, but impaired in mutant HBx. Because mutated HBx gene frequently is found in naturally occurring human HCC , these results are consistent with the hypothesis that co-transactivation and neoplastic transformation are separable functions of HBx (Gottlob et al., 1998) .
The NF-kB signaling pathway is a key component of the cellular response to a variety of extracellular Figure 3 In-vitro-translated wt (CNT) and mutant (CT, MNT and MT) HBx proteins were incubated with glutathione-sepharose beads loaded with GST or GST-p53 (Lanes 2, 3, 5 and 6). To reference input for binding, 20% of the volume of the corresponding in vitro-translated HBx proteins were loaded simultaneously (lanes 1 and 4) Figure 4 The ability of wt HBx (CNT) and HBx mutants (CT, MNT and MT) to transcriptionally transactivate the NF-kBdriven luciferase reporter construct in Hep3B cells grown on 6-well plates. The luciferase activities were measured in a luminometer and the data were normalized by an internal Renilla luciferase vector (pRL-null). (a) Cells were treated with a ®xed amount (0.5 mg) of corresponding DNA with and without TNFa (10 ng/ml) for 24 h. The results represent at least three independent experiments. Wt HBx (CNT) had a higher level of relative luciferase activity than the HBx mutants (CT, MNT and MT) and control DNA with or without TNFa (all P values 50.05 by Student t-test) (b) The data showed a dose-response relationship (dose of DNA ranged from 0 to 5 mg) for wt (CNT) and mutant HBx (CT), treated with and without TNFa for 24 h. Representative data were from at least one experiment testing each sample at dierent dosages stimuli, such as TNFa and interleukin-1 (Baeurele and Baltimore, 1996; . This transcriptional factor also can be activated by dierent oncogenic viral proteins, including human T-cell leukemia virus type 1 Tax (Good and Sun, 1996; Lacoste et al., 1995; Hirai et al., 1994; Sun et al., 1994) , Epstein-Barr virus latent membrane protein 1 (LMP-1) (Herrero et al., 1995) and HBx protein (Chirillo et al., 1996; Su and Schneider, 1996) . In concordance with a previous report , wt HBx can transcriptionally co-transactivate NF-kB luciferase activity, whereas HBx mutants have an attenuated co-transactivation ability. From Western blot analysis, we further demonstrated that, although the steady-state levels of HBx mutants were less than wt HBx, the translated products of HBx mutants were defective in cotransactivation activity. It is possible that HBx mutant proteins have a reduced immunoreactivity to the HBx antibodies used.
NF-kB has divergent apoptotic eects (Baichwal and Baeuerle, 1997). Anti-apoptotic activities were observed following some apoptotic stimuli, including TNF-a, ionizing radiation and the chemotherapeutic agent doxorubicin (Beg and Baltimore, 1996; Liu et al., 1996; Van Antwerp et al., 1996; . Ample evidence for the apoptosis-promoting functions of NF-kB also is available (Grimm et al., 1996; Hettmann et al., 1999; Huang et al., 2000) . The proor anti-apoptotic function of NF-kB may be determined by the nature of the apoptotic stimulus (Bours et al., 2000; Kaltschmidt et al., 2000) . In this study, we showed that while wt HBx has the ability to cotransactivate NF-kB and induce cell death, the HBx mutants failed to do so. This suggests that HBxinduced apoptosis might be associated with the activation of the NF-kB signaling pathway. Further studies are needed to test this hypothesis.
It has been proposed that the co-transactivation and pro-apoptotic function of HBx were linked and inseparable activities (Schuster et al., 2000; Bergametti et al., 1999; Gottlob et al., 1998; Sirma et al., 1998) . Consistent with these studies, our study indicates that wt HBx has the ability to co-transactivate and induce a higher apoptotic rate after prolonged expression; however, HBx mutants lose these activities. Recent investigations showed that it does so probably as a result of cell cycle delay or arrest at the G1/S transition, which was absent in the mutants (Bergametti et al., 1999; Sirma et al., 1999; Park et al., 2000) . The mechanism responsible for the loss of the cotransactivation ability of the HBx is most likely attributed to multiple missense mutations in the cotransactivation domain (Figure 1 ). It also has been hypothesized that the pro-apoptotic activity of wt HBx might contribute to HBV-associated oncogenesis by exerting a selective advantage that favors the emergence of mutated cells (Bergametti et al., 1999) . In this respect, our results provide a possible mechanism of hepatocarcinogenesis for HBx mutants, which are closely associated with liver cancer, but do not possess pro-apoptotic and co-transactivation activity.
p53-mediated apoptosis is an important event for maintaining tissue homeostasis and preventing genomic instability diseases (Lane, 1992 ; Prives, 1993; Lowe et , 1993 Symonds et al., 1994; Levine, 1997; Schwartz and Rotter, 1998; Oren, 1999) . The inactivation of p53-mediated apoptosis by HBx leads to the disruption of the normal cellular surveillance mechanism for eliminating damaged cells. Accordingly, we hypothesized that the translated products of mutant HBx retain their ability to inhibit p53-mediated apoptosis, which is the major tumor suppressor function of p53. The loss of the other functions in mutant HBx also indicates the pathological signi®cance of the attenuation of p53-mediated apoptosis. By providing a selective clonal advantage for preneoplastic or neoplastic hepatocytes expressing the integrated viral gene, these naturally arising mutants may be a clinically relevant mechanism in the development of human HCC.
Materials and methods
Plasmids
The HBx constructs (CNT, CT, MNT and MT) encoding X gene sequences have been cloned into the mammalian expression vector, pcDNA3 (Invitrogen), and puri®ed properly. pC53-SN, encoding human wt p53 under the control of the CMV promoter, were provided by Bert Vogelstein. Pracbgal, a gift of J Yuan (Harvard University), encodes a b-galactosidase (b-gal) gene under the control of chicken bactin promoter. pNF-kB-Luc, provided by John Brady (National Cancer Institute), contains a luciferase gene under the promoter containing NF-kB responsive elements.
Cell culture and microinjection
Low-passaged primary human ®broblasts (GM08402) were obtained from Coriell Institutes for Medical Research (Camden, NJ, USA). These cells were grown in Ham's F10 medium supplemented with 15% fetal bovine serum (FBS) and used for microinjection. The technique of microinjection was performed as described previously (Wang et al., 1995) . In brief, the cells were seeded directly onto the glass coverslips and then microinjected within 48 ± 72 h of plating. p53 and HBx plasmids were injected into the nuclei of cells using a glass microcapillary needle at 100 ng/ml and 200 ng/ml of PBS, respectively. When the HBx contruct was microinjected, pracbgal plasmid was co-injected at 100 ng/ml of PBS to facilitate immunostaining. The pracbgal expression vector was known to induce only a few cell deaths as reported previously (Elmore et al., 1997) . Each plasmid combination was injected into at least 200 cells per experiment, analysed at 24 and 72 h, and tested in at least three independent experiments. Only those experiments with greater than 15 immunopositive cells were included in the analysis. In comparing the eects of dierent combinations of the expression vectors, microinjections were performed on the same slide to minimize variations due to dierences in immunostaining or processing of the slides.
Immunohistochemical analysis of p53, wt and mutant HBx
Cells were ®xed with 4% paraformaldehyde in PBS for 10 min, followed by methanol for 20 min at 24 or 72 h post microinjection. Coverslips were washed in PBS-plus (0.15% glycine and 0.5% BSA in PBS). p53 was detected using antip53 polyclonal CM-1 antibody (1 : 200 dilutions in PBS-plus; Signet Laboratories, Dedham, MA, USA) for 1 h at 378C. Anti-rabbit IgG conjugated with¯uorescein isothiocyanate (FITC) was used as the secondary antibody (1 : 300 dilutions; Vector Laboratories, Burlingame, CA, USA) for 30 min at room temperature. b-gal was visualized using b-gal monoclonal antibody (1 : 50 dilutions; Oncogene Science, Uniondale, NY, USA), followed by FITC-conjugated anti-mouse IgG antibody (1 : 300 dilutions; Vector Laboratories) as described above. Nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Sigma). Cell morphology was visualized in a¯uorescence microscope equipped with both FITC and DAPI ®lter. Apoptotic cells were scored by morphological changes including cytoplasmic blebbing, nuclear condensation and/or fragmentation, and the appearance of apoptotic bodies.
Transfection and in vitro binding assay
In vitro protein translation of various HBx constructs was performed by using Cos-7 cells, which were grown on 100-mm culture plates (Costar, MD, USA) containing Eagle's minimal essential medium supplemented with 10% FBS. Transfection was carried out by Lipofectamine based on the recommended protocol described by the manufacturer (Life Technologies, Gaithersburg, MD, USA). For protein detection, the ECL Western blot detection system (Amersham) was used with the polyclonal anti-HBx antibodies (Elmore et al., 1997) . Preparation of GST and GST-p53 fusion protein, in vitro translation and binding assays were performed essentially as described previously (Wang et al., 1994) . In brief, the GST and GST-fusion proteins were produced in E. Coli and puri®ed on glutathione-sepharose 4B beads according to the manufacturer's instructions (Pharmacia LKB, NJ, USA). Protein concentrations were estimated by Coomasie blue staining of SDS ± PAGE and by comparison to molecular weight standards run on the same gel. To label the in vitro synthesized proteins, the corresponding plasmids were incubated at 308C for 90 min with [ 35 S]-Methionine (Amersham, NJ, USA) in a 1-step in vitro transcription and translation system (Promega, WI, USA). Binding assays were done in 500 ml binding buer (50 mM Tris-HCL (pH 8.0), 120 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.5% Nonidet P40) by incubating the GST and GST-fusion proteins with in vitro translated proteins for 60 min at room temperature. After washing with binding buer, bound proteins were released by boiling in Laemmli buer for 5 min, seperated by SDS ± PAGE and visualized by autoradiography.
Transcriptional transactivational assay
For the luciferase reporter assay, cells were seeded into 6-well plates (Costar, MA, USA) in triplicate at 50 ± 60% con¯uence and co-transfected with 5 ng pNF-kB-Luc along with 500 ng of various HBx constructs in the presence or absence of TNFa (10 ng/ml). For the dose-response relationship, cells were transfected with 0 ± 5 mg of expression vector encoding either wt (CNT) or mutant (CT) HBx. A total of 500 ng pRL-null was added in each transfection as an internal control. pcDNA3, the parental vector, was used to keep the total amount of plasmid DNA constant. Cells were incubated for 24 h prior to harvesting. The luciferase activity was carried out by the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions and measured in a Monolight 2010 luminometer (Analytical Luminescence Laboratory). The relative luciferase activity was normalized by Renilla luciferase activity for the transfection eciency. The comparison of the transactivation activity of dierent HBx constructs represent data from three independent experiments, whereas the reported dose-response results re¯ect representative data from at least one experiment.
